- The launch of Palmeux®/Paliperidone 1-month long-acting injection is supporting ADVANZ PHARMA’s mission to improve patients' lives by providing the specialty medicines they depend on.
- “The launch of Palmeux®/Paliperidone is a next step in the growth journey of ADVANZ. It follows the recent successful introduction of Mytolac®/Myrelez®/Lanreotide” said Steffen Wagner, CEO of ADVANZ PHARMA.
London, UK – 17/02/2023: - ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia, has reached an important milestone with the launch of Palmeux®/Paliperidone 1-month long-acting injection in various European countries, including for example Germany, Spain, Italy, the UK, Ireland, Netherlands, Denmark, Sweden, Norway, and Finland.
This makes ADVANZ PHARMA one of the first companies to bring a Paliperidone 1-month long-acting generic injection to patients and customers in licensed markets and continues ADVANZ PHARMA’s mission to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on.
Paliperidone is a second-generation antipsychotic, also known as an atypical antipsychotic (simultaneous serotonin and dopamine antagonist) for the treatment of schizophrenia in adult patients.